Evidence map›Paper›PMID 42182847›Full record

ArticleOpen forum infectious diseases2026

Invasive Fusariosis: A Retrospective Case Series Evaluating In Vitro Minimum Inhibitory Concentrations and Clinical Response.

Victor Kovac, Sarah P Hammond, Nicolas C Issa, Alexis Liakos, Jessica S Little, Amy C Sherman, Lindsey R Baden, Ann E Woolley

Abstract read
In one paragraph

Article in Open forum infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Victor KovacDivision of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts, USA.ORCID https://orcid.org/0000-0003-1811-6565
Sarah P HammondDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.ORCID https://orcid.org/0000-0002-4271-7443
Nicolas C IssaDivision of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts, USA.ORCID https://orcid.org/0000-0002-6596-0518
Alexis LiakosDivision of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts, USA.ORCID https://orcid.org/0009-0001-6616-920X
Jessica S LittleDivision of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts, USA.ORCID https://orcid.org/0000-0001-8093-5647
Amy C ShermanDivision of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Lindsey R BadenDivision of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Ann E WoolleyDivision of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Invasive fusariosis (IF) is a rare but aggressive infection seen in immunocompromised patients that often exhibits elevated minimum inhibitory concentrations (MICs) to antifungal drugs, making the optimal therapeutic remains unknown. We identified all cases of IF between January 2015 and April 2024 and collected patient characteristics, including clinical presentation, therapy, and 12-week outcomes, as well as organism species identification and susceptibility testing. Twenty-one patients were diagnosed with either proven (n = 14) or probable (n = 7) IF. The mean age was 60 years and 71% were male. Hosts had hematologic disorders in 71% of which 80% had acute leukemia. Seventy-three percent were neutropenic at the time of IF diagnosis and 40% had received allogeneic stem cell transplantation. Infections were localized in 57% and disseminated in 43%. Skin was the most common site of involvement (67%), followed by pulmonary (42%) and sinus (21%). The most common species was

Indexed as

Fusariumhematologic malignancyisavuconazoleposaconazoleterbinafinevoriconazole

Identifiers

PMID42182847
PMCPMC13197842

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.